



## Altimune to Participate in Upcoming Investor Conferences

October 10, 2019 at 7:00 AM EDT

GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will participate in the following investor conferences during the months of October and November:

### ***H.C. Wainwright 3<sup>rd</sup> Annual NASH Investor Conference***

Date: Monday, October 21  
Time: 11:20am ET  
Speaker: M. Scott Harris M.D., Chief Medical Officer  
Location: St. Regis Hotel, New York City  
Webcast: <https://ir.altimmune.com/investors/events-and-presentations>

### ***BIO Investor Forum***

Date: Wednesday, October 23  
Time: 12:45pm ET/9:45am PT  
Speaker: Vipin K. Garg Ph. D., President and Chief Executive Officer  
Location: Westin St. Francis Hotel, San Francisco, CA  
Webcast: <https://ir.altimmune.com/investors/events-and-presentations>

### ***Jefferies 2019 London Healthcare Conference***

Date: November 20 and November 21 (*one-on-one meetings only*)  
Attendees: Vipin K. Garg Ph.D., President and Chief Executive Officer  
Will Brown, Chief Financial Officer  
Location: Waldorf Hilton, London, UK

### **About Altimune**

Altimune is a clinical stage biopharmaceutical company focused on developing treatments for liver diseases and immune modulating therapies. The Company's diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoShield™ and NasoVAX™). For more information on Altimune, please visit [www.altimmune.com](http://www.altimmune.com).

### **Contacts**

Will Brown  
Chief Financial Officer  
Phone: 240-654-1450  
Email: [wbrown@altimmune.com](mailto:wbrown@altimmune.com)

Ashley R. Robinson  
Managing Director LifeSci Advisors  
Phone: 617-535-7742  
Email: [arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)



Source: Altimune, Inc.